Sara S. McCoy - Concepedia

Author

Sara S. McCoy

University of Wisconsin–Madison ORCID

Also Known As

S. Mccoy, S.S. Mccoy, SARA S. McCOY, Sara McCoy, Sara Mccoy, Sara S McCoy, Sara S. McCoy, Sara Safa McCoy

Publications

952

Citations

H-Index

Concepts

All Affiliations

University of Wisconsin–Madison Johns Hopkins University Johns Hopkins Medicine University of Pennsylvania Brown University

About

Sara S. McCoy is an author at University of Wisconsin–Madison specializing in medicine, sjögren’s syndrome, and rheumatology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	219
2	Health Sciences	1	1	17
3	Critical Care Medicine	1	1	36
4	Endocrinology	1	1	17
5	Epidemiology	1	1	17

Sara S. McCoy

Publications

620

Citations

H-Index

Page 1

	Year	Citations
Neurological Complications of Sjögren’s Syndrome: Diagnosis and Management Sara S. McCoy, Alan N. Baer Current Treatment Options in Rheumatology RheumatologyNeurobiology Of DiseaseSjögren’s SyndromeMedicineNeurological Disorder	2017	72
Longterm Outcomes and Treatment After Myocardial Infarction in Patients with Rheumatoid Arthritis Sara S. McCoy, Cynthia S. Crowson, Hilal Maradit Kremers, The Journal of Rheumatology	2013	61
Association of Sjögren's Syndrome With Reduced Lifetime Sex Hormone Exposure: A Case–Control Study Sara S. McCoy, Emmanuel Sampene, Alan N. Baer Arthritis Care & Research	2019	59
Hypothyroidism as a Risk Factor for Development of Cardiovascular Disease in Patients with Rheumatoid Arthritis Sara S. McCoy, Cynthia S. Crowson, Sherine E. Gabriel, The Journal of Rheumatology	2012	58
Scleroderma keratinocytes promote fibroblast activation independent of transforming growth factor beta Sara S. McCoy, Tamra J. Reed, Céline C. Berthier, Lara D. Veeken	2017	56
Symptom‐Based Cluster Analysis Categorizes Sjögren's Disease Subtypes: An International Cohort Study Highlighting Disease Severity and Treatment Discordance Sara S. McCoy, M. Woodham, Christie M. Bartels, Arthritis & Rheumatology	2022	46
Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjögren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study Benjamin A. Fisher, Xavier Mariette, Athena Papas, The Lancet RheumatologySubcutaneous IscalimabWeek 24Phase 2BClinical Trials	2024	39
A National Survey of Burnout and Depression Among Fellows Training in Pulmonary and Critical Care Medicine Michelle Sharp, Kristin M. Burkart, Mark Adelman, CHEST Journal Critical Care MedicineBurnoutPsychiatryFellows TrainingDepression	2020	36
Mycophenolate therapy in interstitial pneumonia with autoimmune features: a cohort study Sara S. McCoy, Zubin Mukadam, Keith C. Meyer, Therapeutics and Clinical Risk Management	2018	35
Ocular Manifestations and Burden Related to Sjögren Syndrome: Results of a Patient Survey Ian J. Saldanha, Vatinee Y. Bunya, Sara S. McCoy, American Journal of Ophthalmology RheumatologySjögren SyndromePatient SurveyOcular DiseaseOphthalmology	2020	33

Page 1